Human Genome Sciences — Investor Presentation (November 2011)
26 slides from Human Genome Sciences's investor presentation, Nov 10, 2011
Slide 1: Benlysta and Beyond
Benlysta(r) And beyond November 10, 2011
Slide 2: Note Regarding Forward-Looking Statements
Note Regarding Forward-Looking Statements 2 This presentation includes statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include those regarding our expectations for BENLYSTA(r) and our financial guidance.
Slide 3: Drivers of Near-Term Growth
DRIVERS OF NEAR-TERM GROWTH 1BENLYSTA is indicated in the U.S. for the treatment of adult patients with active, autoantibody- positive, systemic lupus erythematosus who are receiving standard therapy. Limitations of Use: The efficacy of BENLYSTA has not been evaluated in patients with severe active
Slide 4: Drivers of Long-Term Growth
Drivers of Long-Term Growth BENLYSTA: expand market opportunity Expect to initiate Phase 3 subcutaneous formulation trial around end of 2011 Phase 2/3 vasculitis trial planning underway Proof of concept/exploratory studies in additional indications GSK pipeline, Phase 3s ongoing: Darapladib-cardiova
Slide 5: Redefining the market for SLE treatment
Redefining the market for SLE treatment 5
Slide 6: BENLYSTA initial U.S. market estimate: 200,000 patients
Mild 33% Severe 22% Moderate 45% Initial Target 200,000** 1,500,000 Patients with Lupus and Related Conditions* 325,000 SLE Patients Treated by Rheumatologists** * Per Lupus Foundation of America ** Per primary HGS market research BENLYSTA INITIAL U.S. Market estimate: 200,000 Patients 6
Slide 7: Benlysta positioning in SLE treatment algorithm
Benlysta positioning in SLE treatment algorithm Initial Therapies (persistent symptoms) Anti-malarials Low dose corticosteroids Acute (severe active)1 Chronic Intensified Therapy (persistent symptoms) High dose corticosteroids Immunosuppressants Methotrexate Mycophenolate mofetil Azathioprine 1Use o
Slide 8: Launch update
Launch update 90% of targeted accounts have indicated intent to use BENLYSTA* Less than 10% of key accounts have ordered as of June 30 Approximately 30% have ordered as of September 30 More than 50% of recently surveyed physicians have prescribed Key uptake drivers Access Perceptions of reimbursemen
Slide 9: Key initiatives
Key initiatives New clinical promotional material available to salesforce since August Improves impact of key messages (including identifying appropriate patients for treatment) Speakers bureau recently enhanced Number of speakers increased to approximately 70, up from about 10 at launch Expect thre
Slide 10: Payer reimbursement - relevant for community accounts
Payer reimbursement - relevant for community accounts ~70% of patients More than 40% of key community accounts ordered as of Sept 30 Some rheumatologists hesitant based upon reimbursement delays with previously launched biologics BENLYSTA experience to date positive BENLYSTA covered (via policy or e
Slide 11: Payer distribution for SLE
Payer distribution for sle Note: "Other" = Workers' Compensation, no charge/charity care, blank or unknown Source: Years, 2004 to 2007: National Ambulatory/Medical Care Survey / National Hospital Ambulatory Medical Care Survey, survey conducted by the National Center for Health Statistics Self-Pay C
Slide 12: Patient identification
Patient identification Broad label covers majority of SLE patients Community rheumatologists (initial driver) less experienced with BENLYSTA New promotional materials now available Speaker programs Initial trial and experience Clinical efficacy measurements vary by rheumatologist Physician adoption
Slide 13: Field Implementation in the U.S.
Field Implementation in the U.S. SLE Experts Academic and Large Community Hospitals (465 accounts) Top Community Rheum Infusion Centers (200 Clinics) Other Community Rheum Accounts (1600 clinics) Commercial & Government Payers 18 Medical Science Liaisons (HGS) 69 Account Managers (HGS) 76 Account Ma
Slide 14: Broad Potential Beyond Initial Market Entry in SLE
Proof-of-Concept/ Exploratory Studies Sjogren's Syndrome1 Waldenstrom's Disease1 Transplant1 Idiopathic thrombocytopenic purpura Myasthenia gravis Idiopathic membranous nephropathy Broad Potential Beyond Initial Market Entry in SLE Subcutaneous Formulation May improve convenience for some patients M
Slide 15: BENLYSTA presents a significant opportunity in Europe
BENLYSTA presents a significant opportunity in europe Launched in Germany and several other European countries1 Q3 Reimbursement in place Expect to launch in Spain Q4 Concentrated target group = lean organization Other major markets to follow in coming months France and Italy 15 1Austria, Denmark, F
Slide 16: EU label facilitates targeting of patients
EU label facilitates targeting of patients Label directed to high disease activity patients These patients show a particularly robust response to BENLYSTA For example, low complement / anti-dsDNA+1 Difference in SRI response (BENLYSTA vs placebo) 19.8% vs 11.8% in overall population2 Statistically s
Slide 17: Beyond U.S. and EU
Beyond U.S. and EU Launched in Canada August Indication and recommended use closely aligned with U.S. Regulatory applications currently under review in a number of other countries Regulatory submissions anticipated in additional countries during 2011 Phase 3 program for China, Japan and S. Korea rec
Slide 18: Manufacturing Supply To Meet Demand
Manufacturing Supply To Meet Demand - HGS Ready to deliver; Lonza to Triple Capacity HGS ready to deliver worldwide supply / state-of-the-art capabilities Currently have at least a year's worth of inventory on hand 2 x 20K liters in-house manufacturing capacity for BENLYSTA Sufficient to produce wor
Slide 19: Beyond Benlysta
Beyond Benlysta
Slide 20: Raxibacumab: Treatment for Inhalation Anthrax
RAXIBACUMAB Treatment for Inhalation Anthrax First 20,000 doses delivered H1 2009 to the U.S. Strategic National Stockpile; $163 million in revenue recognized through Q2 2009 45,000 more doses to be delivered over a three-year period; $142 million award; initiated 4Q09 $104 million in revenue recogn
Slide 21: Late-Stage GSK Products Promise Future Growth
Initiation of Phase 3 trial in Asia planned 2011 Initiation of Phase 3 trial of subcutaneous formulation planned 2011 Sales to Strategic National Stockpile under U.S. Government contract Phase 2/3 trial planning underway Formerly FP-1039. Rights acquired March 2011 from FivePrime Therapeutics Raxiba
Slide 22: Darapladib Phase 3 for Cardiovascular Disease
Discovered by GSK based on HGS technology 10% royalty on worldwide sales 20% co-promotion option in North America and Europe CV disease one of the largest markets in the pharmaceutical industry Darapladib Phase 3 for Cardiovascular Disease Lp-PLA2 inhibitor as a potential anti-atherosclerosis agent
Slide 23: Albiglutide Phase 3 for Type 2 Diabetes
Licensed to GSK Fees and milestone payments up to $183 million; up to $150 million still to be received1 Single-digit net royalties on worldwide sales Approximately 18.8 million diagnosed type 2 diabetes patients in the U.S.2 Albiglutide Phase 3 for Type 2 Diabetes Once-a-week GLP-1 agonist Eight Ph
Slide 24: Strong financial position
Strong financial position Pro forma cash and investments at September 30, 2011: $970 million1 Expect cash and investments at December 31, 2011: $870 - $900 million1 Expect 2011 SG&A expense to total $150 - $170 million Expect 2011 R&D expense to total $180 - $220 million2 24 1Gives effect to payment
Slide 25: A Formula for Sustainable Growth
Potential Blockbuster Product Pipeline to Fuel Future Growth Manufacturing Excellence Commercial Readiness World-Class Partner Seasoned Leadership A Formula for Sustainable Growth Building Shareholder Value 25
Slide 26: Thank You
Thank You 26
Human Genome Sciences — Investor Presentation (November 2011) on 6ix